哪里想瘦打哪里！FDA批准Kythera注射抗生素上市在即

你才双下巴，你全家都双下巴！都是可人之心人皆有之。如果说赘肉是每一个希望握有完美身材的“妹纸”或“汉纸”的大敌，那么一个喜感十足的双下巴已是是这些人的命运背叛了。每一分钟，多国都有人为自己的一张大饼脸而倍感执著，虽然握有一个肉感十足的双下巴指头上去是挺有肉感的，但是还是有很多人的心理素质使其未能受压一个双下巴之重。您可千万别笑，这甚至早已费伊一个庞大的的产品。根据英国皮肤外科手术学就会的调查研究显示，68%的英国人对自己的双下巴表示了“厌倦”之情。而有鉴于此，最近Kythera的公司向FDA草拟了其专门打倒双下巴的按摩注射式用药ATX-101。这种用药收尾了许多“胖纸”梦寐以求的功能，哪里想瘦打哪里，已是是定点减肥。不必以为这种近乎任性的用药只是一个嘲讽，在FDA的下属的皮肤和眼科用药署长就会的无记名投票里，专家可是以17：0的超高票数一致赞同其上市。或许是因为这些专家里也有很多饱受双下巴之苦吧。FDA也将计划于月份的5月13日之前对其这两项就此决定。如果一切顺利的话，Kythera的公司计划于月份下半年将该产品上市，分析社就会大众预计这一用药的营业收入将少于3亿美元之多。随着按摩用药的产品的愈发增大，Kythera的公司已是是下了一步好棋。的公司于去年以8400万美元的价格从其前合作伙伴拜耳手里收回了这种用药的全部公民权。而Kythera的公司也希望更进一步为就此在按摩用药的产品里攻城拔寨。就在上个月，Kythera的公司和Actelion的公司达成经济效益2700万美元的合作协议，共同开发一种失败过的抗击炎症用药，而这种用药被认为可能会开发出一种治疗皮肤炎的用药。具体英文另据：Kythera ($KYTH) won the unanimous support of an FDA advisory panel for its fat-busting injection, rolling toward approval with a first-of-its-kind treatment.The agency's independent Dermatologic and Ophthalmic Drugs Advisory Committee voted 17-0 that the drug's benefits outweighed its risks for patients looking to reduce submental fat, or double chin. The FDA is not required to follow its panels' votes, though it most commonly does, and the agency has promised to make a final decision on the injection by May 13. If all goes according to plan, Kythera plans to launch the drug, ATX-101, in the second half of this year.The biotech's shares he more than tripled since it pulled off a $73 million IPO in 2012, rising steadily as investors bet ATX-101 can carve out a space on the aesthetic market and potentially lure a Big Pharma acquirer. Kythera is pitching the injection as a much-needed nonsurgical option for double chin reduction, citing an American Society for Dermatologic Surgery survey that estimates 68% of Americans are "bothered" by submental fat.Kythera regained full rights to ATX-101's potential last year, orchestrating an $84 million deal to buy out ex-partner Bayer. And the drug, a synthetic version of the fat-blasting deoxycholic acid, could bring in more than $300 million a year once approved, Leerink yst Seamus Fernandez has said."This milestone demonstrates our commitment to developing first-in-class aesthetic products through a focus on scientific rigor and innovation," Kythera CEO Keith Leonard said in a statement. "At Kythera, we remain focused on investing in novel treatments that will allow aesthetic physicians to better meet the needs of their patients."Kythera is also focused on raising some cash now that it has a likely approval ahead. The biotech filed for a $125 million offering as soon as the market closed on Monday. Its share price was down several points at the end of the day.Beyond its top prospect, Kythera is working to build out a pipeline of aesthetic medicines. Last month, the California biotech signed a $27 million deal with Actelion ($ATLN) to get its hands on a once-failed anti-inflammatory medicine that could he a future as a treatment for hair loss.